Home  |  Contact

Cellosaurus SiMa (CVCL_1695)

[Text version]

Cell line name SiMa
Synonyms SIMA
Accession CVCL_1695
Resource Identification Initiative To cite this cell line use: SiMa (RRID:CVCL_1695)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Biotechnology: Used in a bioassay to measure botulinum toxin serotype A (BoNT/B) activity. Together with the monoclonal antibody produced by hybridoma 2E2A6 (CVCL_RA98).
Doubling time: 48-100 hours (PubMed=10686945); ~34-100 hours, highly variable (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.65
Native American0
East Asian, North2.52
East Asian, South0
South Asian1.24
European, North63.44
European, South32.14
Disease Adrenal gland neuroblastoma (NCIt: C4827)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_RG05 (SiMa GFP-VAMP2)
Sex of cell Male
Age at sampling 1Y8M
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; PubMed=25877200

Markers:
AmelogeninX,Y
CSF1PO10,12
D2S133819,21
D3S135818
D5S81811
D7S82010
D8S117913,14
D13S31712
D16S53912,13
D18S5114,16
D19S43313,14
D21S1128
FGA20,22
Penta D14
Penta E11,12
TH019,9.3
TPOX8
vWA15,17

Run an STR similarity search on this cell line
Publications

PubMed=10686945; DOI=10.1016/S0165-4608(98)00269-6
Marini P., MacLeod R.A.F., Treuner C., Bruchelt G., Bohm W., Wolburg H., Schweizer P., Girgert R.
SiMa, a new neuroblastoma cell line combining poor prognostic cytogenetic markers with high adrenergic differentiation.
Cancer Genet. Cytogenet. 112:161-164(1999)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23185348; DOI=10.1371/journal.pone.0049516
Fernandez-Salas E., Wang J., Molina Y., Nelson J.B., Jacky B.P.S., Aoki K.R.
Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay.
PLoS ONE 7:E49516-E49516(2012)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cross-references
Cell line collections DSMZ; ACC-164
Cell line databases/resources CLDB; cl4300
CCLE; SIMA_AUTONOMIC_GANGLIA
Cell_Model_Passport; SIDM00395
Cosmic-CLP; 753620
DepMap; ACH-000099
LINCS_LDP; LCL-1979
Ontologies CLO; CLO_0009018
Biological sample resources BioSample; SAMN03470930
BioSample; SAMN10988579
Chemistry resources ChEMBL-Cells; CHEMBL3308828
ChEMBL-Targets; CHEMBL2366067
GDSC; 753620
PharmacoDB; SIMA_1378_2019
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM563363
GEO; GSM887572
GEO; GSM888655
GEO; GSM1366410
GEO; GSM1670423
Other Wikidata; Q54953497
Polymorphism and mutation databases Cosmic; 753620
Cosmic; 2485949
LiGeA; CCLE_027
Entry history
Entry creation04-Apr-2012
Last entry update06-Sep-2019
Version number24